2024
Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon
Yadem A, Armstrong J, Sarimollaoglu M, Kiki Massa C, Ndifo J, Menyaev Y, Mbe A, Richards K, Wade M, Zeng Y, Chen R, Zhou Q, Meten E, Ntone R, Tchuedji Y, Ullah S, Galanzha E, Eteki L, Gonsu H, Biris A, Suen J, Boum Y, Zharov V, Parikh S. Noninvasive in vivo photoacoustic detection of malaria with Cytophone in Cameroon. Nature Communications 2024, 15: 9228. PMID: 39455558, PMCID: PMC11511992, DOI: 10.1038/s41467-024-53243-z.Peer-Reviewed Original ResearchConceptsClearance of parasitemiaDetection of malariaMalaria-infected red blood cellsDiagnosed symptomatic casesCross-sectional cohortUncomplicated malariaMalaria diagnosticsMalaria infectionRed blood cellsSymptomatic casesTarget antigenAsymptomatic reservoirCameroonian adultsFlow cytometer platformBlood samplesReservoir of infectionBlood cellsLack sensitivityLongitudinal cohortMolecular assaysMalariaIRBCPoint-of-careCohortQuantitative PCR
2022
Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definition
2020
Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, Boum Y, Brito M, Charoenkwan P, Clements A, Cui L, Deng Z, Egesie OJ, Espino FE, von Fricken ME, Hamid MMA, He Y, Henriques G, Khan WA, Khim N, Kim S, Lacerda M, Lon C, Mekuria AH, Menard D, Monteiro W, Nosten F, Oo NN, Pal S, Palasuwan D, Parikh S, Pasaribu A, Poespoprodjo JR, Price DJ, Roca-Feltrer A, Roh ME, Saunders DL, Spring MD, Sutanto I, Ley-Thriemer K, Weppelmann TA, von Seidlein L, Satyagraha AW, Bancone G, Domingo GJ, Price RN. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLOS Medicine 2020, 17: e1003084. PMID: 32407380, PMCID: PMC7224463, DOI: 10.1371/journal.pmed.1003084.Peer-Reviewed Original ResearchConceptsG6PD activity measurementsG6PD activityDiagnostic Accuracy Studies-2 toolDormant liver stagesRisk of biasGlucose-6-phosphate dehydrogenase deficiencyStudy-level heterogeneityNormal control samplesReference diagnostic methodInter-study variabilityGlucose-6-phosphate dehydrogenase activityMalaria patientsHaematological conditionsLiver stagesRadical cureP. ovalePlasmodium vivaxPubMed searchIntermediate deficiencySystematic reviewDiagnostic thresholdMale medianStudy participantsMedian activityDiagnostic implicationsAn Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment
Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrobial Agents And Chemotherapy 2020, 64: 10.1128/aac.02394-19. PMID: 32071050, PMCID: PMC7179577, DOI: 10.1128/aac.02394-19.Peer-Reviewed Original ResearchConceptsDrug-drug interactionsAntiretroviral therapyDolutegravir-based antiretroviral therapyPotential drug-drug interactionsDay 7 concentrationsIndividual participant dataConcomitant efavirenzLopinavir-ritonavirLumefantrine exposureLumefantrine regimenAntituberculosis treatmentUncomplicated malariaAntiretroviral treatmentHIV infectionTreatment failurePopulation pharmacokineticsLumefantrine concentrationsLarger body weightBody weightEfavirenzParticipant dataLumefantrineMalariaAdult participantsRifampinEfavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 140-147. PMID: 31929402, PMCID: PMC7061940, DOI: 10.1097/qai.0000000000002237.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlkynesAnti-HIV AgentsAntimalarialsAnti-Retroviral AgentsArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsBenzoxazinesCyclopropanesDrug CombinationsDrug InteractionsFemaleHIV InfectionsHumansLumefantrineMalariaMalaria, FalciparumPregnancyProspective StudiesUgandaYoung AdultConceptsEfavirenz-based antiretroviral therapyImpact of efavirenzPregnant womenArtemether-lumefantrineMalaria treatmentAntiretroviral therapyEfavirenz therapyIntensive PK evaluationPK exposure parametersPlasmodium falciparum malariaEffect of efavirenzActive metabolite dihydroartemisininAntimalarial exposureClinical responseFalciparum malariaPregnant HIVTreatment regimenNonsignificant reductionClinical pharmacokinetic studiesPK evaluationDrug interactionsLumefantrine concentrationsHIVTreatment durationPK samples
2019
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. The Lancet 2019, 393: 1517-1526. PMID: 30878222, PMCID: PMC6459982, DOI: 10.1016/s0140-6736(18)32321-3.Peer-Reviewed Original ResearchConceptsMass drug administrationCluster-randomised trialIntervention groupMalaria episodesControl groupDrug AdministrationDetection cohortMass administrationIvermectin mass drug administrationUncomplicated malaria episodesClinical malaria episodesMalaria transmission seasonSingle oral dosesControl of malariaAdverse eventsCumulative incidencePrimary outcomeOral dosesEligible participantsAdverse reactionsFurther dosesTwo-armExclusion criteriaTransmission seasonTreatment phase
2015
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria
Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrobial Agents And Chemotherapy 2015, 60: 1274-1282. PMID: 26666942, PMCID: PMC4775973, DOI: 10.1128/aac.01605-15.Peer-Reviewed Original ResearchConceptsNonpregnant adultsPregnant womenArtemether-lumefantrineFalciparum malariaUncomplicated Plasmodium falciparum malariaPharmacokinetics of artemetherPregnant Ugandan womenSix-dose regimenFirst-line regimenUncomplicated falciparum malariaPlasmodium falciparum malariaHigh transmission settingsUncomplicated malariaClinical responsePharmacokinetic exposureTerminal eliminationClinical outcomesThird trimesterTreatment responseAntimalarial efficacyProphylactic periodUgandan womenPharmacokineticsDrug resistanceOverall pharmacokinetics